

## SBRI Healthcare End of Phase 1 Report Form

This report addresses a deliverable for organisations as indicated by the SBRI Healthcare Phase 1 contract. This report must be received electronically through the SBRI Healthcare FluidReview portal by 1700hrs, 14 working days after the 'Completion date' defined in your Phase 1 contract. An identical printed copy must be received at Health Enterprise East no later than two days after the deadline.

Please send the completed report by email to <a href="mailto:sbrienquiries@hee.co.uk">sbrienquiries@hee.co.uk</a> and one identical printed copy to:

Joop Tanis SBRI Healthcare Director Health Enterprise East Ltd Milton Hall Ely Road Cambridge CB24 6WZ

## The aims of this document are:

- To report on the work undertaken, its success in meeting the project's objectives and to provide information that may be used in the assessment of Phase 2 applications (please note that a separate Phase 2 application form will need to be submitted. Companies will be notified by Health Enterprise East of the timescale for submitting Phase 2 applications if applicable in due course);
- To explain expenditure; and,
- To provide a confidential report on the findings during Phase 1 for NHS and AHSN stakeholders.

The report should be completed by the lead contractor, with input from any sub-contractors or project partners if appropriate. When describing technical solutions, please regard your audience as being someone familiar with the field, but not an expert in the technology. Please also explain in the report the meaning of all the acronyms used and avoid the extensive use of technical jargon.

Diagrams or pictures may be added, however be sure to keep the <u>maximum number of pages to 30 sides of A4 in Arial 10pts minimum font size</u>.

The authors are allowed to edit the format and size of all the cells and tables in this form to better fit the text on each section. Namely, the authors are allowed to expand or reduce the size of the cells, paste new cells or extra pages, etc. However please do not exceed the maximum number of 30 pages for the complete form. Word limits are provided only as a guide to maximum expected length of responses. If a question is felt to be inapplicable to your project, please indicate this with 'N/A'.

For enquiries, please contact the SBRI Healthcare team at Health Enterprise East on Tel: 01223 928

040 or sbrienquiries@hee.co.uk	

1. Details	
SBRI Healthcare project title:	
Registered Company Name:	
Registered Address:	
Town/City:	
Postcode:	
County:	
Report Author:	
Telephone Number:	
E-mail Address:	
Total Contract Value: (£s)	
Contract Start Date: End Date:	

## Milestones and key test for Phase 1 as set out in Schedule 1 of the SBRI Healthcare contract.

#	Milestone	Date	Resource	Success Criteria
1				
2				
3				
4				
5				

6			
7			
8			
9			
10			
Key	Test:		

2. In reference to the milestones described above, indicate any changes that have occurred. Include the reasons for these changes and circumstances that assisted or hindered the progress of the project and the actions being taken to overcome them.

Milestone	Actual Date Delivered	Changes to milestone (include alterations in outcome, delivery date, and/or resources)	Outcome achieved

<u> </u>	-	•	

3. To what extent has the project met the key test set out in the Phase	1 contract?
	(max. 500 words)
4. Have there been any changes in the management structure or person	onnel
administering the award in the project?	Jillei
	(max. 300 words)

5. Please provide a detailed summary of the outputs obtained by the project, include a description of the current iteration of the product and any associated service offering, along with any available data generated as part of trials/pilots etc. being carried out.
(max. 6 pages)
6. Describe the new, innovative aspects of the work, including findings and techniques obtained by the project. Clearly identify where any such innovations represent an
advance over the state of the art.
(max. 600 words)

7. List any new Intellectual Property (IP) which has been filed. Th	is could include	
trademarks and designs, as well as patents.		
	(max. 300 words)	
8. Will you be applying for, or have you applied for NICE technolog		
8. Will you be applying for, or have you applied for NICE technolog	y appraisal? And if so, wh (max. 300	
8. Will you be applying for, or have you applied for NICE technolog		
8. Will you be applying for, or have you applied for NICE technolog		
8. Will you be applying for, or have you applied for NICE technolog		
8. Will you be applying for, or have you applied for NICE technolog		
8. Will you be applying for, or have you applied for NICE technolog		
8. Will you be applying for, or have you applied for NICE technolog		
8. Will you be applying for, or have you applied for NICE technology		
8. Will you be applying for, or have you applied for NICE technology		
8. Will you be applying for, or have you applied for NICE technology		
8. Will you be applying for, or have you applied for NICE technolog		

9. Please describe the product's planned route to market (distribution	, sales, etc).
	(max. 500 words)
10. What is the envisaged target pricing for the product(s)?	
10. What is the envisaged target pricing for the product(s)?	(may 200 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)
10. What is the envisaged target pricing for the product(s)?	(max. 300 words)

11. What are the margins anticipated for this product?	
	(max. 300 words)
12. Please indicate the product(s) intended market launch date (eg Q	1 2017\
12. Please indicate the product(s) intended market launch date (eg Q	
	(max. 300 words)

13. Provide a description of the health economic benefits that for the NHS, including the numbers of patients/users expected savings to the NHS.		
	(max. 500 words)	
AA Duradala a kadaf arada wa afaka arankat alaa faratkia aranda at in i	the MILIC and become difference	-4-1
14. Provide a brief review of the market size for this product in including growth rate of the market, main competitors and pote		etc.),
14. Provide a brief review of the market size for this product in including growth rate of the market, main competitors and pote		
	ntial adoption issues.	

15. Who are you envisaging the customers for your product(s) will be?	
	(max. 300 words)
16. What are your sales forecasts for the developed product(s) for years 1, 2 and	d 3 post market
launch?	
	(max. 300 words)

17. What are your plans for internationalisation?	(max. 300 words)
18. Will additional funding will be required to commercialise the production of the expected capital investment and the plans to raise this.	duct(s)? If so,
	duct(s)? If so, (max. 300 words)

19. Insert the budget costs for the project, as displayed in Schedule 2 of your SBRI Healthcare contract, into the report below.

Give a brief description of how the SBRI Healthcare funds were spent with reference to the original budget and explain any significant variations. Confirm the final total project expenditure (£'s VAT included).

A separate financial spreadsheet template is provided to describe Phase 1 costs in further detail.

	Budgeted Costs (£)	Actual Costs (£)	Expenditure Description	Reasons for variance between budget and actual costs
Labour Costs				
Materials Cost				
Capital Equipment Costs				
Sub Contract Costs				
Travel & Subsistence Costs				
Indirect Costs				
Other Costs				
Total Q1 Costs (including VAT)				

20. Describe any potential long-term collaborations/partnerships er project and the roles these played. This description should include a	
NHS, social care or third sector providers.	
	(max. 500 words)
21. Describe the trials or pilots undertaken by the project. Please in	
of the number of patients/users that benefited from your product d	uring these
trials/pilots.	(max. 500 words)
	(iliax. 500 Wolds)

22. How many clinicians/clinical teams across how many trusts/orga	anisations have been
involved in developing the technology?	
	(max. 300 words)
22 Describe how you worked with your local AHSN in respect of this	s project What level
23. Describe how you worked with your local AHSN in respect of the	s project. What level
23. Describe how you worked with your local AHSN in respect of thi of support have you received?	
	s project. What level (max. 300 words)

25. Has this project provided your company with any new skills or know-how that growth in the forthcoming years?	t will enable
	(max. 300 words)
25. Has the SBRI Healthcare funding enabled you to create or safeguard jobs with	nin your
25. Has the SBRI Healthcare funding enabled you to create or safeguard jobs with organisation? If so, how many?	
	nin your (max. 400 words)

26. Include details of additional funding (e.g. venture capital, equity investment or other institutional funding), leveraged as a result of the SBRI Heatlhcare award.
Please also include details of any awards or achievements directly related to the project.
(max. 300 words)
27. Provide additional information that may be pertinent. This may be in the form of text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.
text, pictures, diagrams, data, graphs that support the work. If not detailed at an earlier a stage in this report, provide specific key performance data for the product. Please note this section is for additional information only that could not be included in other sections.

## 28. Declaration of expenditure.

Your financial controller must provide here comment regarding accuracy and completeness of:

- 1. Answer to question 19, describing expenditure on Phase 1
- 2. The separate financial template spreadsheet detailing expenditure on Phase 1. As explained on the spreadsheet template, the financial controller should also print, sign and date the front page of the spreadsheet, scanning it to a protected PDF suitable for electronic transmission along with the entire worksheet to Health Enterprise East.

This section must be signed below by the financial controller.

<u>Separate pages and/or cells can be added for this section</u>, to supplement the Finance Controller's comment below, provided the total for the whole completed report does not exceed 30 sides of A4, Arial font 10pts minimum.

Finance Controller's Comment:
Signed Date
Print name
Company

29. Declaration from t	ne author
I confirm that the infor	mation given on this report is complete and correct.
Company name:	
Signed:	Date
Print name:	
Company position:	

-END-